EMCURE PHARMACEUTICALS L vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of EMCURE PHARMACEUTICALS L (EMCURE) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads EMCURE vs SUNPHARMA on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

36.57
P/E ratio
40.40
7.11
P/B ratio
5.57
0.17%
Dividend yield
0.83%
₹48.76
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

20.10%
Return on equity
16.00%
24.00%
Return on capital
21.00%
20.00%
EBITDA margin
30.00%
10.22%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

15.42%
Revenue CAGR (3Y)
10.03%
18.75%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹33,810 Cr
Market cap
₹4.64L Cr
₹9,204 Cr
Revenue
₹58,462 Cr
₹941 Cr
Net profit
₹11,509 Cr
0.31
Debt / equity
0.06
EMCURE PHARMACEUTICALS L
  • ["Stock is trading at 7.06 times its book value"]
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
EMCURE PHARMACEUTICALS L full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

EMCURE PHARMACEUTICALS L vs SUN PHARMACEUTICAL IND L: Share Price, Valuation & Which to Buy | DocStoX